List of articles with "Vanda Pharmaceuticals"

FDA Lifts Tradipitant Hold

FDA Lifts Tradipitant Hold

United States FDA Approval Washington Vanda Pharmaceuticals Tradipitant
Vanda's Tradipitant Update

Vanda's Tradipitant Update

USA Washington Vanda Pharmaceuticals Tradipitant Motion Sickness
Tradipitant's Promise

Tradipitant's Promise

United States Washington GLP-1 Agonists Vanda Pharmaceuticals Tradipitant
October Health Updates

October Health Updates

USA New York Novo Nordisk Vanda Pharmaceuticals Health Press Releases
Vanda Q3 2025 Financials

Vanda Q3 2025 Financials

United States Washington Vanda Pharmaceuticals Fanapt BIosanti
Islanders and Vanda Team Up

Islanders and Vanda Team Up

USA New York Vanda Pharmaceuticals New York Islanders NHL sponsorship
Vanda Pharmaceuticals Partnership

Vanda Pharmaceuticals Partnership

USA Washington, D.C. Vanda Pharmaceuticals Monumental Sports Capital One Arena
Vanda and FDA Partnership

Vanda and FDA Partnership

United States Washington D.C. Vanda Pharmaceuticals Hetlioz Tradipitant
Insights on HETLIOZ®

Insights on HETLIOZ®

USA Washington Vanda Pharmaceuticals HETLIOZ® insomnia study
Vanda Investor Conferences

Vanda Investor Conferences

USA New York Investor Conferences Vanda Pharmaceuticals VNDA
Innovative Treatment for PV

Innovative Treatment for PV

United States Washington Vanda Pharmaceuticals Polycythemia Vera VGT-1849B
Vanda Urges FDA Review

Vanda Urges FDA Review

USA Washington Vanda Pharmaceuticals Hetlioz FDA Review
Vanda's Legal Victory

Vanda's Legal Victory

United States Washington Vanda Pharmaceuticals Hetlioz Jet Lag
Vanda's Q2 2025 Growth

Vanda's Q2 2025 Growth

USA Washington Vanda Pharmaceuticals Fanapt Bysanti
Vanda at ASCP 2025

Vanda at ASCP 2025

United States Scottsdale Vanda Pharmaceuticals Bysanti ASCP Annual Meeting
Vanda at Mizuho Summit

Vanda at Mizuho Summit

United States New York City Vanda Pharmaceuticals Mizuho Summit Neuro Ophthalmology
Vanda Q1 2025 Results

Vanda Q1 2025 Results

USA Washington Vanda Pharmaceuticals Fanapt Bysanti
FDA Decision for Bysanti™

FDA Decision for Bysanti™

USA Washington FDA Vanda Pharmaceuticals Bysanti™
FDA Delays Vanda Hearing

FDA Delays Vanda Hearing

USA Washington FDA Vanda Pharmaceuticals Tradipitant
Vanda Pharmaceuticals at AAN 2025

Vanda Pharmaceuticals at AAN 2025

USA San Diego Vanda Pharmaceuticals CMT2S ASO Therapy
Bysanti™ NDA Submission

Bysanti™ NDA Submission

United States Washington Vanda Pharmaceuticals Bysanti™ NDA Submission
VCA-894A for CMT Type 2S

VCA-894A for CMT Type 2S

United States Washington Vanda Pharmaceuticals Charcot-Marie-Tooth VCA-894A
Vanda's 2024 Success

Vanda's 2024 Success

United States Washington Vanda Pharmaceuticals Fanapt Hetlioz
Vanda and AnaptysBio Unite

Vanda and AnaptysBio Unite

USA Washington Vanda Pharmaceuticals Imsidolimab AnaptysBio
VGT-1849A Orphan Drug Status

VGT-1849A Orphan Drug Status

USA Washington Vanda Pharmaceuticals JAK2 VGT-1849A

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.